Lu-177-PSMA-617 for Prostate Cancer

(ESCENDO Trial)

This trial explores the safety and optimal initial dose of Lu-177-PSMA-617, a radioactive drug, for prostate cancer that resists standard hormone therapy and has metastasized. The treatment uses this radioactive drug to target and potentially kill cancer cells. Researchers aim to determine if a higher dose in the first treatment cycle proves more effective. Men with prostate cancer that continues to grow despite low hormone levels and who have cancer spots visible on a specific type of scan might be suitable candidates for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

Research has shown that Lutetium Lu 177 vipivotide tetraxetan is generally safe for people with prostate cancer. Studies have found it can help extend life and slow cancer growth. In previous studies, most participants tolerated the treatment well. However, some experienced side effects such as lower blood counts and dry mouth, which were usually manageable. The FDA has approved the treatment for certain types of prostate cancer, indicating a well-understood safety profile.¹²³⁴⁵

Unlike the standard treatments for prostate cancer, which typically include hormone therapy, surgery, and chemotherapy, Lu-177-PSMA-617 offers a more targeted approach. This treatment uses a radioactive particle, Lutetium-177, which is linked to a molecule that specifically targets prostate-specific membrane antigen (PSMA) present on prostate cancer cells. By directly delivering radiation to the cancer cells, it aims to minimize damage to healthy tissues and enhance treatment precision. Researchers are excited because this method could offer a more effective and less toxic alternative to existing therapies, potentially improving outcomes for patients with advanced prostate cancer.

Research has shown that Lu-177-PSMA-617 holds promise for treating prostate cancer, particularly when the cancer has spread and resists hormone therapy. This trial will explore various dosing levels of Lu-177-PSMA-617, which targets a protein called PSMA on prostate cancer cells. Upon attachment, it releases radiation directly to the cancer cells, aiding in their destruction. Early results suggest that the initial dose in a series might be most effective at delivering radiation to the cancer. Studies indicate that this targeted approach may improve outcomes for patients with advanced prostate cancer that resists other treatments.⁶⁷⁸⁹¹⁰